Literature DB >> 26810224

Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses.

Lichen Jing1, Kerry J Laing1, Lichun Dong1, Ronnie M Russell1, Russell S Barlow2, Juergen G Haas3,4, Meena S Ramchandani1, Christine Johnston1, Soren Buus5, Alec J Redwood6, Katie D White7, Simon A Mallal6,7, Elizabeth J Phillips6,7, Christine M Posavad8,9, Anna Wald1,10,8,9, David M Koelle1,2,8,9,11.   

Abstract

The Alphaherpesvirinae subfamily includes HSV types 1 and 2 and the sequence-divergent pathogen varicella zoster virus (VZV). T cells, controlled by TCR and HLA molecules that tolerate limited epitope amino acid variation, might cross-react between these microbes. We show that memory PBMC expansion with either HSV or VZV enriches for CD4 T cell lines that recognize the other agent at the whole-virus, protein, and peptide levels, consistent with bidirectional cross-reactivity. HSV-specific CD4 T cells recovered from HSV-seronegative persons can be explained, in part, by such VZV cross-reactivity. HSV-1-reactive CD8 T cells also cross-react with VZV-infected cells, full-length VZV proteins, and VZV peptides, as well as kill VZV-infected dermal fibroblasts. Mono- and cross-reactive CD8 T cells use distinct TCRB CDR3 sequences. Cross-reactivity to VZV is reconstituted by cloning and expressing TCRA/TCRB receptors from T cells that are initially isolated using HSV reagents. Overall, we define 13 novel CD4 and CD8 HSV-VZV cross-reactive epitopes and strongly imply additional cross-reactive peptide sets. Viral proteins can harbor both CD4 and CD8 HSV/VZV cross-reactive epitopes. Quantitative estimates of HSV/VZV cross-reactivity for both CD4 and CD8 T cells vary from 10 to 50%. Based on these findings, we hypothesize that host herpesvirus immune history may influence the pathogenesis and clinical outcome of subsequent infections or vaccinations for related pathogens and that cross-reactive epitopes and TCRs may be useful for multi-alphaherpesvirus vaccine design and adoptive cellular therapy.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26810224      PMCID: PMC4761520          DOI: 10.4049/jimmunol.1502366

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  75 in total

1.  THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS.

Authors:  R E HOPE-SIMPSON
Journal:  Proc R Soc Med       Date:  1965-01

2.  POSSIBLE ANTIGENIC RELATIONSHIP BETWEEN VARICELLA ZOSTER VIRUS AND HERPES SIMPLEX VIRUS.

Authors:  J G KAPSENBERG
Journal:  Arch Gesamte Virusforsch       Date:  1964-09-09

3.  Statistical practice in high-throughput screening data analysis.

Authors:  Nathalie Malo; James A Hanley; Sonia Cerquozzi; Jerry Pelletier; Robert Nadon
Journal:  Nat Biotechnol       Date:  2006-02       Impact factor: 54.908

4.  A Shannon entropy analysis of immunoglobulin and T cell receptor.

Authors:  J J Stewart; C Y Lee; S Ibrahim; P Watts; M Shlomchik; M Weigert; S Litwin
Journal:  Mol Immunol       Date:  1997-10       Impact factor: 4.407

5.  Infection of cells with varicella-zoster virus down-regulates surface expression of class I major histocompatibility complex antigens.

Authors:  J I Cohen
Journal:  J Infect Dis       Date:  1998-05       Impact factor: 5.226

6.  Intact TRL 9 and type I interferon signaling pathways are required to augment HSV-1 induced corneal CXCL9 and CXCL10.

Authors:  Todd Wuest; Bobbie Ann Austin; Satoshi Uematsu; Manoj Thapa; Shizuo Akira; Daniel J J Carr
Journal:  J Neuroimmunol       Date:  2006-08-01       Impact factor: 3.478

7.  A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Authors:  M N Oxman; M J Levin; G R Johnson; K E Schmader; S E Straus; L D Gelb; R D Arbeit; M S Simberkoff; A A Gershon; L E Davis; A Weinberg; K D Boardman; H M Williams; J Hongyuan Zhang; P N Peduzzi; C E Beisel; V A Morrison; J C Guatelli; P A Brooks; C A Kauffman; C T Pachucki; K M Neuzil; R F Betts; P F Wright; M R Griffin; P Brunell; N E Soto; A R Marques; S K Keay; R P Goodman; D J Cotton; J W Gnann; J Loutit; M Holodniy; W A Keitel; G E Crawford; S-S Yeh; Z Lobo; J F Toney; R N Greenberg; P M Keller; R Harbecke; A R Hayward; M R Irwin; T C Kyriakides; C Y Chan; I S F Chan; W W B Wang; P W Annunziato; J L Silber
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

8.  Identification of immunodominant regions and linear B cell epitopes of the gE envelope protein of varicella-zoster virus.

Authors:  W J Fowler; M Garcia-Valcarcel; M S Hill-Perkins; G Murphy; D R Harper; D J Jeffries; N R Burns; S E Adams; A J Kingsman; G T Layton
Journal:  Virology       Date:  1995-12-20       Impact factor: 3.616

9.  Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions.

Authors:  D M Koelle; L Corey; R L Burke; R J Eisenberg; G H Cohen; R Pichyangkura; S J Triezenberg
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

10.  HLA-DQB1 codon 57 is critical for peptide binding and recognition.

Authors:  W W Kwok; M E Domeier; M L Johnson; G T Nepom; D M Koelle
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more
  31 in total

1.  Highly conserved intragenic HSV-2 sequences: Results from next-generation sequencing of HSV-2 UL and US regions from genital swabs collected from 3 continents.

Authors:  Christine Johnston; Amalia Magaret; Pavitra Roychoudhury; Alexander L Greninger; Anqi Cheng; Kurt Diem; Matthew P Fitzgibbon; Meei-Li Huang; Stacy Selke; Jairam R Lingappa; Connie Celum; Keith R Jerome; Anna Wald; David M Koelle
Journal:  Virology       Date:  2017-07-13       Impact factor: 3.616

Review 2.  Herpes zoster and the search for an effective vaccine.

Authors:  N Arnold; I Messaoudi
Journal:  Clin Exp Immunol       Date:  2016-07-25       Impact factor: 4.330

3.  Selective Expression of CCR10 and CXCR3 by Circulating Human Herpes Simplex Virus-Specific CD8 T Cells.

Authors:  Michael T Hensel; Tao Peng; Anqi Cheng; Stephen C De Rosa; Anna Wald; Kerry J Laing; Lichen Jing; Lichun Dong; Amalia S Magaret; David M Koelle
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

4.  T Cell Immunity to Varicella-Zoster Virus in the Setting of Advanced HIV and Multiple Varicella-Zoster Virus Recurrences.

Authors:  Rachel A Bender Ignacio; Meena S Ramchandani; Kerry J Laing; Christine M Johnston; David M Koelle
Journal:  Viral Immunol       Date:  2016-11-21       Impact factor: 2.257

5.  Bolstering the Number and Function of HSV-1-Specific CD8+ Effector Memory T Cells and Tissue-Resident Memory T Cells in Latently Infected Trigeminal Ganglia Reduces Recurrent Ocular Herpes Infection and Disease.

Authors:  Arif A Khan; Ruchi Srivastava; Aziz A Chentoufi; Elizabeth Kritzer; Sravya Chilukuri; Sumit Garg; David C Yu; Hawa Vahed; Lei Huang; Sabrina A Syed; Julie N Furness; Tien T Tran; Nesburn B Anthony; Christine E McLaren; John Sidney; Alessandro Sette; Randolph J Noelle; Lbachir BenMohamed
Journal:  J Immunol       Date:  2017-05-24       Impact factor: 5.422

6.  Human Asymptomatic Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP13/14 (UL47) Preferentially Recall Polyfunctional Effector Memory CD44high CD62Llow CD8+ TEM Cells and Protect Humanized HLA-A*02:01 Transgenic Mice against Ocular Herpesvirus Infection.

Authors:  Ruchi Srivastava; Arif A Khan; Sumit Garg; Sabrina A Syed; Julie N Furness; Hawa Vahed; Tiffany Pham; Howard T Yu; Anthony B Nesburn; Lbachir BenMohamed
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

7.  Genome-Wide Approach to the CD4 T-Cell Response to Human Herpesvirus 6B.

Authors:  Derek J Hanson; Olga Tsvetkova; Guilhem F Rerolle; Alexander L Greninger; Allesandro Sette; Lichen Jing; Victoria L Campbell; David M Koelle
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

8.  Proteome-Wide Zika Virus CD4 T Cell Epitope and HLA Restriction Determination.

Authors:  Victoria L Campbell; LeAnn Nguyen; Elise Snoey; Christopher L McClurkan; Kerry J Laing; Lichun Dong; Alessandro Sette; Cecilia S Lindestam Arlehamn; Danny M Altmann; Rosemary J Boyton; Justin A Roby; Michael Gale; Mars Stone; Michael P Busch; Phillip J Norris; David M Koelle
Journal:  Immunohorizons       Date:  2020-08-04

9.  Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107+ CD8+ T Cells That Infiltrate the Corneas and Trigeminal Ganglia of Humanized HLA Transgenic Rabbits and Protect against Ocular Herpes Challenge.

Authors:  Arif A Khan; Ruchi Srivastava; Hawa Vahed; Soumyabrata Roy; Sager S Walia; Grace J Kim; Mona A Fouladi; Taikun Yamada; Vincent T Ly; Cynthia Lam; Anthony Lou; Vivianna Nguyen; Undariya Boldbaatar; Roger Geertsema; Nigel W Fraser; Lbachir BenMohamed
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

10.  Viral Genetics Modulate Orolabial Herpes Simplex Virus Type 1 Shedding in Humans.

Authors:  Meena S Ramchandani; Lichen Jing; Ronnie M Russell; Tran Tran; Kerry J Laing; Amalia S Magaret; Stacy Selke; Anqi Cheng; Meei-Li Huang; Hong Xie; Eric Strachan; Alex L Greninger; Pavitra Roychoudhury; Keith R Jerome; Anna Wald; David M Koelle
Journal:  J Infect Dis       Date:  2019-03-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.